Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Aperture Venture Partners is a New York-based venture capital firm founded around 2002, focusing on early-stage investments in the healthcare sector. The firm has established itself as a key player in medical devices, pharmaceuticals, healthcare IT/services, and diagnostics. With a team of partners who possess deep clinical and operational expertise, Aperture is well-positioned to support entrepreneurs in addressing significant unmet clinical needs through innovative technologies.
As of mid-2025, Aperture has participated in approximately 74 investments, achieving 27 exits and supporting 7 portfolio companies that reached the public markets. The firm remains actively deploying capital, with notable recent activities including a follow-on investment in Neuros Medical in July 2025 and an exit in Nalu Medical in October 2025. Aperture's commitment to early-stage healthcare innovation is evident in its diverse portfolio and strategic partnerships.
Aperture Venture Partners primarily targets early-stage companies within the healthcare sector, specifically in medical devices, biopharmaceuticals, healthcare IT/services, and diagnostics. The firm invests between $1 million and $5 million in seed, Series A, and Series B rounds. Aperture emphasizes a founder-centric approach, leveraging the clinical backgrounds of its partners to provide operational engagement and strategic guidance to portfolio companies.
The firm seeks to partner with exceptional entrepreneurs who are addressing significant unmet clinical needs with novel technologies. Aperture's investment thesis is firmly rooted in the belief that deep industry knowledge and active board engagement are critical for the success of portfolio companies. This approach allows them to navigate the complexities of the healthcare landscape effectively.
Aperture Venture Partners has a diverse portfolio of 74 companies, with notable exits including:
Current active portfolio companies include:
Tony Natale, M.D. - Managing Partner. Dr. Natale has a background in General Surgery and Otolaryngology. He has previously worked with Prism Ventures and MDS Capital and has co-founded or led investments in multiple medtech companies, including Mako Surgical. He holds a BA from the University of Virginia, an MD from the University of Florida, and an MBA from Yale.
Paul E. Tierney, Jr. - Managing Partner. Tierney has over 30 years of experience in global investment. He is a co-founding principal of Gollust, Tierney and Oliver / Coniston Partners, which manages a $1 billion active value fund. He is also an Adjunct Professor at Columbia Business School. He earned his MBA from Harvard (Baker Scholar) and a BA from Notre Dame.
Eric H. Sillman - Partner. Sillman has experience in M&A, equity, and debt from his time at UBS, as well as strategy consulting at The Parthenon Group. He holds an MBA from Harvard and a BA from Brown.
Thomas P. Cooper, M.D. - Partner. Dr. Cooper is a healthcare entrepreneur who founded Spectrum Emergency Care and Correctional Medical Services, among others, with combined revenues exceeding $2 billion. He has a strong background in healthcare operations and holds an MD.
To pitch Aperture Venture Partners, founders should send an email to info@aperturevp.com. It is important to include a comprehensive pitch deck that outlines the startup's vision, market analysis, and team qualifications. The firm appreciates clarity and detail in presentations.
While specific response time expectations are not disclosed, founders should anticipate a thorough review process given the firm's focus on early-stage investments in healthcare. Warm introductions may enhance the chances of receiving a timely response.
In July 2025, Aperture Venture Partners participated in a follow-on investment in Neuros Medical, a company focused on neuromodulation for chronic nerve pain. The specific details of the investment were not disclosed.
In October 2025, the firm exited its investment in Nalu Medical, which specializes in implantable microstimulators for chronic pain management. This exit marks another successful outcome for Aperture's portfolio.
What are Aperture Venture Partners' investment criteria?
Aperture focuses on early-stage healthcare companies, particularly in medical devices, pharmaceuticals, healthcare IT/services, and diagnostics. They invest between $1 million and $5 million in seed, Series A, and Series B rounds.
How can I pitch to Aperture Venture Partners?
Founders can reach out via email at info@aperturevp.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and team background.
What makes Aperture different from other venture capital firms?
Aperture's partners possess deep clinical and operational expertise, which allows them to provide significant operational support and strategic guidance to portfolio companies. This clinical background enhances their credibility in the healthcare sector.
What is the geographic focus of Aperture Venture Partners?
The firm primarily invests in companies based in the United States, focusing on the healthcare sector.
What is the typical involvement of Aperture after investment?
Aperture takes an active role in board engagement and operational support, leveraging their partners' clinical expertise to guide portfolio companies through challenges and growth opportunities.
What is the firm's track record in terms of exits?
Aperture has achieved 27 exits from its portfolio, with several companies reaching significant valuations, including notable IPOs and acquisitions.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.